Clinical Trials Logo

Optic Ischaemic Neuropathy clinical trials

View clinical trials related to Optic Ischaemic Neuropathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT04239196 Recruiting - Clinical trials for Giant Cell Arteritis

Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA

TOCIAION
Start date: September 10, 2020
Phase: Phase 2
Study type: Interventional

AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains. Subcutaneous tocilizumab, a targeted biotherapy, recently received marketing authorization for the treatment of GCA, but only demonstrated at yet that it can allow steroid dose sparing. The aim of this study is to assess the benefit of tocilizumab and IV steroids combination or IV steroids alone, in the treatment of AION due to GCA.